Otsuka, Lundbeck eye Alzheimer's indication in FDA adcomm for Rexulti label expansion

Otsuka and Lundbeck’s brexpiprazole is getting a joint FDA adcomm to potentially expand the mental health drug’s label for the treatment of agitation associated with Alzheimer’s dementia.